{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-020876","form_type":"8-K","ticker":null,"cik":"0001845459","company_name":"NKGen Biotech, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.515627+00:00","generated_at":"2026-05-15T23:47:01.739587+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"NKGen Biotech secures additional $343K loan from AlpineBrook; total note principal rises to $27.1M","bullets":["Additional $343,000 loan from AlpineBrook Capital; total secured note principal increased to $27,101,106.","Loan funded on Feb 20, 2026; interest accrues from that date.","This is the fifth amendment to the note, with prior amendments in January 2026.","Borrowers include NKGen Biotech and NKGen Operating Biotech; CEO Paul Song signed."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-020876","json":"https://secwatch.observer/filing/0001213900-26-020876.json","markdown":"https://secwatch.observer/filing/0001213900-26-020876.md","text":"https://secwatch.observer/filing/0001213900-26-020876.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026020876/0001213900-26-020876-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026020876/ea0277453-8k_nkgenbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:47:01.739587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c062194156072165e8b9e84c70b79046e3c178b5","claim":"NKGen Biotech, Inc. incurred loan of $343,000 with AlpineBrook Capital GP I Limited.","evidence_excerpt":"The Alpine Fourth Amendment provides an additional $343,000 of funding to the Borrowers (the \"Fifth Additional New Loan\"). As a result, the principal amount of the Note was increased to $27,101,106.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026020876/0001213900-26-020876-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$343,000"},{"label":"Counterparty","value":"AlpineBrook Capital GP I Limited"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"62ba9fb12b10959f4196c12609af0fcd922228cf","claim":"NKGen Biotech, Inc. amended Alpine Fourth Amendment with AlpineBrook Capital GP I Limited valued at $343,000 (effective 2026-02-20).","evidence_excerpt":"On February 20, 2026, NKGen Biotech, Inc. (the “Company”) and NKGen Operating Biotech, Inc., a Delaware corporation (together with the Company, the “Borrowers”), entered into a fourth amendment (the “Alpine Fourth Amendment”) to that certain secured promissory note with AlpineBrook Capital GP I Limited, dated January 5, 2026, as amended by that certain amendment to secured promissory note dated January 12, 2026, that certain amendment no. 2 to secured promissory note dated January 23, 2026, and that certain amendment no. 3 to secured promissory note dated January 30, 2026 (the “Note”). The Alpine Fourth Amendment provides an additional $343,000 of funding to the Borrowers (the “Fifth Additional New Loan”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026020876/0001213900-26-020876-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"AlpineBrook Capital GP I Limited"},{"label":"Value","value":"$343,000"},{"label":"Effective","value":"2026-02-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}